Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10530234 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL13276440 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL6469498 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL6245109 | 1.00 | KDM4E (0.33) | KDM4EGAAPOLBTDP1HPGD | |
| SCHEMBL3225586 | 0.96 | — | — | |
| SCHEMBL10796699 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL16161480 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL2113593 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL8909769 | 0.90 | GAA (0.31) | GAAPOLBTDP1 | |
| SCHEMBL19293544 | 0.90 | GAA (0.31) | GAAPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4213843-B1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2024121264-A1 | INSECTICIDAL COMPOUND BASED ON PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-13 | — | — | WO | claimed |
| WO-2024121262-A1 | INSECTICIDAL COMPOUND BASED ON PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-13 | — | — | WO | claimed |
| US-20240018140-A1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | claimed |
| EP-4213843-A2 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3389643-B1 | NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF | BHARAT BIOTECH INT LTD (IN) | 2023-05-03 | — | — | EP | claimed |
| CN-115745765-A | Preparation method of p-bromoalkylcyclohexanone compounds | 浙大宁波理工学院 | 2023-03-07 | — | — | CN | claimed |
| WO-2022060763-A2 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-03-24 | — | — | WO | claimed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | claimed |
| EP-1730148-A4 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LAB (US) | 2009-08-19 | — | — | EP | claimed |
| WO-2007028051-A2 | NOVEL IMIDAZO BASED HETEROCYCLES | ABBOTT LABORATORIES (US) | 2007-03-08 | — | — | WO | claimed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | claimed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | KDM4E 403/4885GAA 2356/4885POLB 970/4885 |
| US-20240018140-A1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | KDM4E 3855/4885GAA 3/4885POLB 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.